Macrophages of malignant glioma TME are characterized by their plasticity and heterogeneity; however, in a dichotomy approach where two extreme types of macrophage phenotypes co-exist in gliomas’ TME, pro-tumoral M2 macrophages with low expression of IL-12, IL-23, and a high expression of IL-10 and TGF-β have become an attractive therapeutic target to help eradicate this type of tumor. This evidence concerns the gene IL10 and neoplasm.